Avion Pharmaceuticals, a specialty pharmaceutical company, participated as an exhibitor at the annual Nurse Practitioners in Women’s Health Annual Meeting, held September 26-28th at the Hilton Bayfront in San Diego, California. The Annual Meeting was a great opportunity to meet so many of those critical to women’s care.
Featured at the meeting was Avion’s newest addition to the Prenate® Vitamin Family, Prenate® AM. Prenate® AM eases symptoms commonly associated with ordinary morning sickness, including nausea and vomiting. Nausea and omiting are common in pregnancy. Vitamin B6 and Ginger, both key dietary ingredients in Prenate® AM, have been recommended for the conservative management of nausea and vomiting in early pregnancy.1,2
“Avion is a proud to support women’s health initiatives and excited to continue our partnership with NPWH. Prenate® AM is an exciting addition to Avion’s Prenate® portfolio that is important to share with the Nurse Practioner community. As part of the spectrum of prenatal nutritional support, we believe it critical that new OB patients have access to a prenatal vitamin that promotes tolerance to ensure supplementation of key vitamins, minerals and folic acid in the diet. Prenate® AM is designed to help those women who suffer from nausea and vomiting during pregnancy. ACOG (American College of Obstetrics and Gynecology) recommends Vitamin B6 as first line support,” stated Mike Sullivan, Vice President, Sales and Marketing, for Avion Pharmaceuticals.
Sullivan added, “ Avion Pharmaceuticals is proud to be sharing our newest portfolio addition to support women’s health at the NPWH meeting. Avion’s goal is to continue expand on new and innovative products that help promote the health and well-being of moms and babies.”
About Avion Pharmaceuticals, LLC
Avion Pharmaceuticals, LLC., is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women’s Heath and Dermatology therapeutic areas. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.